pharma
dog
News
when
Latest
Archive
by source
All Sources
Sources Page
Jobs
department
Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access
therapeutic area
Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease
location & type
Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →
Drugs
by stage
Marketed
Phase 3
Phase 2
Phase 1
Preclinical
browse
Most catalysts
Recently active
All drugs →
Companies
Patent cliff
Calendar
what
Trial readouts
PDUFA dates
Approvals
Earnings
when
Upcoming
Month grid
Recently passed
◐
Sign In
Subscribe
home
jobs
news
search
Rare Disease · news · pharmadog
← back to Rare Disease
News · Rare Disease
840
stories
10d
Chutes & Ladders—Travere chief makes way for former Amicus CEO
fiercebiotech
10d
Lilly’s latest China drug deal; Immunovant’s setback in lupus
biopharma dive
10d
Kyverna steps closer to FDA-first CAR T for an autoimmune condition with durability data
biospace
10d
Roche inks up to $2B deal with Atavistik for new cardiometabolic drugs
biospace
10d
Kyverna says long-term data bolster FDA submission for rare autoimmune CAR-T
endpoints
10d
Roche pens backloaded $2B deal with Atavistik to discover allosteric CVRM drugs
fiercebiotech
11d
Berlin Seeds Recalls Alfalfa Sprouting Seed Because of Possible Health Risk
fda recalls
11d
Baby KJ's gene editing drug cost $1.65M to make, Fyodor Urnov says
endpoints
11d
Kyverna ‘resetting conversation’ with 1-year miv-cel data as autoimmune CAR-T peers hit safety snags
fiercebiotech
11d
Roche-Ionis’ RNA therapy reduces kidney disease marker, opening path to swift FDA nod
biospace
11d
Novartis bets up to $900M for radioligand therapy from China’s BoomRay
biospace
11d
Ionis-Otsuka offer 'groundbreaking' improvement in function and survival for genetic type of ALS
biospace
11d
The latest in the legal saga for youth gender-affirming care in the U.S.
stat
11d
Novo’s turnaround plan, weight loss wins, Ultragenyx’s Sanfilippo approval, IPO blitz
biospace
11d
9 companies hiring in Pennsylvania now
biospace
12d
ReCode CEO Suliman leaves cystic fibrosis mission in mentee’s hands
biospace
12d
China’s surging biotech sector represents both competition and lifeline for the US
biospace
12d
Opinion: Former FDA commissioners: Heidi Overton has an opportunity to strengthen the FDA
stat
12d
Viking achieves 'maintenance trifecta' as GLP-1/GIP dual agonist exceeds expectations
biospace
12d
Lilly presents early data supporting GLP-1/GIP candidate's potential in depression, alcohol use disorder
biospace
12d
STAT+: Novo may be getting a better deal than expected with Medicare’s Bridge program
stat
12d
2026 IPO blitz continues with 4 new biotech filings
biospace
12d
GSK aiming to ‘balance West and East’ after Hansoh deal success showed China’s potential
fiercebiotech
12d
Lexeo takes up the Mantle in $8M acquisition for Friedreich ataxia assets
fiercebiotech
12d
Otsuka heads to FDA as Ionis-partnered ALS drug hits primary phase 3 endpoint
fiercebiotech
12d
Opinion: Social media bans are passing around the world. How will we know if they help teens?
stat
13d
Beacon eye gene therapy hits mark in late-stage study
biopharma dive
13d
STAT+: What a vote on Grail’s cancer detection test could mean for the company, patients, and regulators
stat
13d
Western licensing deals for Chinese radioligand therapies to jump in 2027, Sleuth forecasts
biospace
13d
Sleuth forecasts 2027 jump in Western license deals for Chinese radioligand therapies
biospace
← prev
page 3 of 28
next →
